Advanced Neurosciences Research, Llc

Fort Collins, Colorado 80528

0 studies enrolling now · 16 studies all time

What they study most

Alzheimer's Disease, Chronic Migraine, Episodic Migraine, Heart Septal Defects, Atrial, Migraine, Migraine Disorders, Migraine, With or Without Aura, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) — Running, not enrolling
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• ESCAPE Migraine Trial — Stopped early
• A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed